肝胆胰外科杂志2024，Vol.36Issue(3)：144-149,6.DOI:10.11952/j.issn.1007-1954.2024.03.003
HAIC在不可切除肝癌合并高流量肝动脉门静脉瘘的短期疗效及安全性
Short-term efficacy and safety of hepatic arterial infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma with high-flow hepatic arterioportal shunts
陈彦晖 1张玉冰 1尹韵清 1沈新颖1
作者信息
- 1. 暨南大学第二临床医学院/深圳市人民医院 介入放射科,广东 深圳 518020
- 折叠
摘要
Abstract
Objective To observe the short-term efficacy and safety of FOLFOX-HAIC in treatment of unresectable hepatocellular carcinoma combined with high-flow hepatic arterioportal shunts(APS).Methods The clinical data of 30 patients with unresectable hepatocellular carcinoma combined with high-flow APS who received FOLFOX-HAIC from Jun.2020 to Jan.2023 were retrospectively collected(HAIC group),and the clinical data of 30 patients in the same target population who underwent transcatheter arterial chemoembolization(TACE)during the same period were also collected(TACE group).The APS improvement rate,objective response rate of tumors and adverse reactions were compared between the two groups.Results The HAIC group showed significantly better results in terms of APS improvement rate(83.3%vs 56.7%,χ2=5.079,P=0.047),objective response rate of tumor lesions(76.7%vs 46.7%,χ2=5.711,P=0.017)and median progression-free survival(PFS)(9.5 months vs 5.4 months,Log-rank χ2=10.832,P=0.001)compared to the TACE group.The incidence of thrombocytopenia in postoperative patients was significantly higher in the HAIC group than in the TACE group(P<0.05).On the other hand,the incidence of postoperative patients with increased alanine transaminase and alkaline phosphatase was significantly higher in the TACE group than in the HAIC group(P<0.05).No serious adverse events were observed.Conclusion HAIC is effective and safe treatment option for improving fistulas and controlling tumors in patients with unresectable hepatocellular carcinoma combined with APS.关键词
肝细胞癌/肝动脉门静脉瘘/肝动脉灌注化疗/肝经动脉化疗栓塞/并发症Key words
hepatocellular carcinoma/arterioportal shunts/hepatic arterial infusion chemotherapy/transarterial chemoembolization/complication分类
医药卫生引用本文复制引用
陈彦晖,张玉冰,尹韵清,沈新颖..HAIC在不可切除肝癌合并高流量肝动脉门静脉瘘的短期疗效及安全性[J].肝胆胰外科杂志,2024,36(3):144-149,6.
